Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy
REDWOOD CITY, Calif., Oct. 15, 2024 ( GLOBE NEWSWIRE ) -- Biomea Fusion, Inc. ( "Biomea" ) ( Nasdaq: BMEA ) , a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and ...
| Ticker |
Sentiment |
Impact |
|
BMEA
|
Neutral
|
19 %
|
|
META
|
Neutral
|
5 %
|
